ストックスクリーナーアプリを入手
16.30
2.57%
-0.43
前日終値:
$16.73
開ける：
$16.71
24時間の取引高:
474.04K
Relative Volume:
0.79
時価総額：
$967.36M
収益：
-
当期純損益:
$-85.21M
株価収益率:
-8.6243
EPS:
-1.89
ネットキャッシュフロー:
$-68.53M
1週間 パフォーマンス:
-3.38%
1か月 パフォーマンス:
-24.92%
6か月 パフォーマンス:
-24.26%
1年 パフォーマンス:
-28.23%
1日の値動き範囲:
$15.88
$16.71
1週間の範囲:
$15.88
$18.05
52週間の値動き範囲:
$13.30
$25.37
Enliven Therapeutics Inc Stock (ELVN) Company Profile
ELVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
16.30 | 992.88M | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-16 | 開始されました | Goldman | Buy |
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
Enliven Therapeutics CSO sells $84k in shares By Investing.com - Investing.com Nigeria
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 5,000 Shares of Stock - MarketBeat
Enliven Therapeutics CSO sells $84k in shares - Investing.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 6.1%Here's What Happened - MarketBeat
First Week of February 2026 Options Trading For Enliven Therapeutics (ELVN) - Nasdaq
Portfolio Shifts: Is Enliven Therapeutics Inc. stock near bottom after decline2025 Volatility Report & Daily Entry Point Trade Alerts - moha.gov.vn
Will Enliven Therapeutics Inc. stock benefit from AI adoption2025 Top Decliners & Fast Exit/Entry Strategy Plans - Улправда
Is Enliven Therapeutics Inc. stock near bottom after declineFed Meeting & Free Weekly Watchlist of Top Performers - Улправда
Technical Reactions to ELVN Trends in Macro Strategies - Stock Traders Daily
What risks investors should watch in Enliven Therapeutics Inc. stockJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - DonanımHaber
Is Enliven Therapeutics Inc. stock a buy before product launchesJuly 2025 Volume & Verified Stock Trade Ideas - DonanımHaber
How Enliven Therapeutics Inc. stock reacts to oil prices2025 Top Gainers & Long-Term Investment Growth Plans - DonanımHaber
How resilient is Enliven Therapeutics Inc. stock in market downturnsWeekly Trend Report & Low Volatility Stock Suggestions - DonanımHaber
Will Enliven Therapeutics Inc. stock gain from strong economy2025 Biggest Moves & Real-Time Buy Zone Alerts - Улправда
Enliven Therapeutics (ELVN) Stock Analysis Report | Financials & Insights - Benzinga
Enliven Therapeutics (NASDAQ: ELVN) registers shares for 2025 equity inducement plan - Stock Titan
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - Markets Financial Content
VIX Spike: How resilient is Enliven Therapeutics Inc stock in market downturnsQuarterly Trade Report & Risk Managed Investment Signals - moha.gov.vn
Enliven Therapeutics Earnings Notes - Trefis
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN - Defense World
CEO moves at Prolynx, Centessa, Kyowa Kirin, Enliven, Expression - BioCentury
Enliven Therapeutics (ELVN) officer-director discloses no owned securities - Stock Titan
Enliven Therapeutics Appoints Richard Fair as CEO - The Globe and Mail
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock - MarketBeat
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - Nasdaq
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling - MarketBeat
Enliven Therapeutics appoints Rick Fair as new CEO - Investing.com
Enliven Therapeutics, Inc. Announces Management Changes - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO, shares down - TradingView — Track All Markets
Enliven Therapeutics Appoints Rick Fair as CEO - marketscreener.com
Enliven Therapeutics appoints Rick Fair as new CEO By Investing.com - Investing.com South Africa
Enliven Therapeutics Appoints New CEO and Director - TradingView — Track All Markets
[8-K] Enliven Therapeutics, Inc. Reports Material Event | ELVN SEC FilingForm 8-K - Stock Titan
Enliven Therapeutics announces new CEO to drive next phase of development - marketscreener.com
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PR Newswire
COO Patel Sells 6,663 ($140.1K) Of Enliven Therapeutics Inc [ELVN] - TradingView — Track All Markets
Top investors say Enliven Therapeutics Inc (ELVN) ticks everything they need - setenews.com
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Yahoo Finance
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Enliven Therapeutics: ENABLE trial shows promise in treating atypical fusion CML - Traders Union
Trading the Move, Not the Narrative: (ELVN) Edition - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Enliven Therapeutics Inc stock benefit from AI adoptionJuly 2025 Setups & Long-Term Capital Growth Strategies - moha.gov.vn
Affinity Asset Advisors LLC Buys Shares of 400,000 Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) and PreveCeutical Medical (OTCMKTS:PRVCF) Head-To-Head Analysis - Defense World
Can Enliven Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Report & Free Low Drawdown Momentum Trade Ideas - Newser
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound - Sahm
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade - sharewise.com
Ready to Jump After Recent Trade: Enliven Therapeutics Inc (ELVN) - setenews.com
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Dec 19 '25 |
Sale |
16.84 |
5,000 |
84,206 |
897,688 |
| Kunkel Lori Anne | Director |
Dec 17 '25 |
Option Exercise |
1.12 |
15,958 |
17,873 |
30,712 |
0.08%
0.21%
大文字化:
|
ボリューム (24 時間):